(Reuters) -Eli Lilly ( LLY ) said on Wednesday it is partnering with Walmart ( WMT ) to expand access to Lilly's weight-loss drug Zepbound, which will be offered for pick-up at Walmart ( WMT ) pharmacies nationwide by mid-November.

Lilly and rival Novo Nordisk started offering vials at discounted prices on their respective websites to expand access and stave off competition from compounded versions or cheaper copies of their weight-loss drugs.

Lilly has been providing all approved doses of Zepbound to cash-paying customers through its website LillyDirect, which was launched last year.

The drugmaker said Walmart ( WMT ) pharmacies will offer Zepbound single-dose vials in all approved strengths, with the lowest dose starting at $349 per month with self-pay.